SLGL trades 32.8% above Wall Street's consensus target of $50.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SLGL achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, Sol-Gel Technologies Ltd. (SLGL) has a Wall Street consensus price target of $50.00, based on estimates from 6 covering analysts. With the stock currently trading at $74.41, this represents a potential downside of -32.8%. The company has a market capitalization of $209M.
Analyst price targets range from a low of $50.00 to a high of $50.00, representing a 0% spread in expectations. The median target of $50.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 5 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SLGL trades at a trailing P/E of -33.8x. Analysts expect EPS to grow -1579.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
DERMJourney Medical Corporation | $187M | $6.79 | $11.75 | +73.0% | Buy | 104.5x | 3 |
PRGOPerrigo Company plc | $1.4B | $10.05 | $36.20 | +260.2% | Hold | 4.7x | 36 |
VYNEVYNE Therapeutics Inc. | $28M | $0.65 | — | — | — | — | — |
SKINThe Beauty Health Company | $92M | $0.71 | $1.53 | +114.7% | Hold | — | 14 |
GDRXGoodRx Holdings, Inc. | $988M | $2.85 | $3.08 | +8.1% | Hold | 9.2x | 24 |
NKTRNektar Therapeutics | $1.3B | $65.39 | $149.60 | +128.8% | Buy | — | 33 |
PODDInsulet Corporation | $11.1B | $157.74 | $220.79 | +40.0% | Buy | 24.3x | 50 |
PAHCPhibro Animal Health Corporation | $1.3B | $31.81 | $49.00 | +54.0% | Buy | 10.4x | 14 |
ACRSAclaris Therapeutics, Inc. | $605M | $5.02 | $10.60 | +111.2% | Buy | — | 16 |
DAREDaré Bioscience, Inc. | $30M | $2.10 | — | — | — | — | — |
Quick answers to the most common questions about buying SLGL stock.
SLGL's consensus price target is $50, -32.8% below the current price of $74.41. The 6 analysts tracking SLGL see downside risk at present valuations.
SLGL has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 5 Buy/Strong Buy ratings. The consensus 12-month price target of $50 implies -32.8% downside from current levels.
SLGL's current price is $74.41 with a consensus target of $50 (-32.8% implied move). Analyst estimates suggest the stock is overvalued at current levels.
The most bullish Wall Street analyst has a price target of $50 for SLGL, while the most conservative target is $50. The consensus of $50 represents the median expectation. These targets typically reflect 12-month expectations.
SLGL is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SLGL stock forecast based on 6 Wall Street analysts shows a consensus price target of $50, with estimates ranging from $50 (bear case) to $50 (bull case). The median consensus rating is "Buy".
Analysts are cautious on SLGL, with 0 Sell ratings and a price target of $50 (-32.8% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SLGL analyst price targets range from $50 to $50, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $50 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.